Literature DB >> 7828622

Serum amylase and tissue polypeptide antigen as biochemical indicators of salivary gland injury during iodine-131 therapy.

A Becciolini1, S Porciani, A Lanini, A Benucci, A Castagnoli, A Pupi.   

Abstract

The study evaluated the possibility of using serum alpha-amylase and tissue polypeptide antigen (TPA) as biochemical markers of radiation injury in the salivary gland of patients with thyroid carcinoma treated with iodine-131. The results demonstrated that the two molecules increased 1 day after 131I administration and returned to near control values on the 3rd day. The increase was greater and longer lasting in those patients treated with the higher 131I administered activity. However, when the patients were divided into groups based on recovery time, which determined patients with different radionuclide elimination rates, the increase in the two molecules was greater and more lasting in those subjects with a longer period of hospitalization. A comparison with the values obtained from patients with tumours of the head and neck treated with external radiotherapy demonstrated that after the 1st day of treatment the salivary gland received an absorbed dose which, based on alpha-amylase levels, ranged between 0.24 and 1.89 Gy and, based on TPA levels, between 0.28 and 2.29 Gy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7828622     DOI: 10.1007/bf00181068

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  13 in total

1.  Post-irradiation hyperamylasemia as a biological dosimeter.

Authors:  B Dubray; T Girinski; H D Thames; A Becciolini; S Porciani; C Hennequin; G Socié; M Bonnay; J M Cosset
Journal:  Radiother Oncol       Date:  1992-05       Impact factor: 6.280

2.  Effects of irradiation with conventional and multiple daily fractionation on serum amylase activity.

Authors:  A Becciolini; S Porciani; A Lanini; A Chiavacci; E Cellai
Journal:  Acta Oncol       Date:  1987       Impact factor: 4.089

3.  Plasma amylase activity as a biochemical indicator of radiation injury to salivary glands.

Authors:  A Becciolini; G Giannardi; L Cionini; S Porciani; C Fallai; L Pirtoli
Journal:  Acta Radiol Oncol       Date:  1984

4.  Sialadenitis following iodine-131 therapy for thyroid carcinoma.

Authors: 
Journal:  J Nucl Med       Date:  1985-07       Impact factor: 10.057

5.  Side effects of "rational dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma.

Authors:  D Van Nostrand; J Neutze; F Atkins
Journal:  J Nucl Med       Date:  1986-10       Impact factor: 10.057

6.  Treatment of malignant thyroid disease.

Authors:  W H Blahd
Journal:  Semin Nucl Med       Date:  1979-04       Impact factor: 4.446

7.  Serum tissue polypeptide antigen (TPA): a marker of acute injury of salivary glands during radiation therapy.

Authors:  A Becciolini; M S Tommasi; S Porciani; B Fantappiè; E Cellai; A Chiavacci
Journal:  Int J Radiat Oncol Biol Phys       Date:  1987-09       Impact factor: 7.038

8.  Prognostic significance of tissue polypeptide antigen (TPA) in head and neck carcinomas.

Authors:  A Becciolini; S Porciani; A Lanini; M Tommasi; P Olmi; A Chiavacci
Journal:  Acta Oncol       Date:  1993       Impact factor: 4.089

9.  Specificity and basis of the tissue polypeptide antigen.

Authors:  B Björklund; V Björklund
Journal:  Cancer Detect Prev       Date:  1983

10.  Sialadenitis following I-131 therapy for thyroid carcinoma: concise communication.

Authors:  P Allweiss; G D Braunstein; A Katz; A Waxman
Journal:  J Nucl Med       Date:  1984-07       Impact factor: 10.057

View more
  2 in total

1.  Salivary glands ultrasound examination after radioiodine-131 treatment for differentiated thyroid cancer.

Authors:  F Brozzi; T Rago; W Bencivelli; F Bianchi; P Santini; P Vitti; A Pinchera; C Ceccarelli
Journal:  J Endocrinol Invest       Date:  2012-04-05       Impact factor: 4.256

2.  Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials.

Authors:  Arunrat Auttara-Atthakorn; Jaruwan Sungmala; Thunyarat Anothaisintawee; Sirimon Reutrakul; Chutintorn Sriphrapradang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-29       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.